Trulove, Susan2015-10-292015-10-292009-02-09http://hdl.handle.net/10919/62570AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. today announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds.text/htmlIn CopyrightResearchAstraZeneca licenses novel antidepressant compounds discovered by Mayo Clinic, Virginia Tech collaborationPress releaseVirginia Tech. University Relations